Overview

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Aprea Therapeutics

Treatments:

Acalabrutinib
Rituximab
Venetoclax